Krystal Biotech, Inc. · NASDAQ:KRYS
Krystal Biotech — Q4 2024 Earnings Presentation
14 slides from Krystal Biotech's earnings presentation, Feb 19, 2025
Slide 1: Fourth Quarter and Full Year 2024 Financial and Operating Results
Fourth Quarter and Full Year 2024 Financial and Operating Results February 19, 2025 © Copyright 2025 Krystal Biotech, Inc. All rights reserved.
Slide 2: Forward Looking Statements and Disclosures
Forward Looking Statements and Disclosures This presentation, which includes the accompanying oral presentation, contains forward-looking statements that involve substantial risks and uncertainties. Any statements in this presentation about future expectations, plans and prospects for Krystal Biotec
Slide 3: Drivers of Long-Term Sustainable Growth
Drivers of Long-Term Sustainable Growth ▪ VYJUVEK launch delivers rapid revenue growth – Over $290M in net US VYJUVEK revenue in 2024 and over $341M since launch in Q3 2023 – Steady pace of new reimbursement approvals underpins long-term growth in the U.S. – Growth trajectory bolstered by Europe and
Slide 4: Over $341M in VYJUVEK Revenue Since Launch
Over $341M in VYJUVEK Revenue Since Launch US$ Millions $91.1 $83.8 $70.3 $42.1 $45.3 $8.6 3Q 2023 4Q 2023 1Q 2024 2Q 2024 3Q 2024 4Q 2024 ▪ Over $290M in revenue in 2024 | Gross margin of 95% in 4Q |Gross to net in 4Q was 16% Krystal | 4
Slide 5: Over 510 Reimbursement Approvals as of February 2025
Over 510 Reimbursement Approvals as of February 2025 Reimbursement Approval Splits Payer Commercial 45% Medicaid 39% Other 16% 85% Compliance to Weekly Therapy While on Drug RDEB DDEB As of 4Q 2024 DEB Subtype 69% 31% Age Group 6 months to 10 Years 11 to 20 21 Years and 97% Years Over Dosing in Home
Slide 6: Field Tactics are Driving Sustained Demand and Expanding Prescriber Base
Field Tactics are Driving Sustained Demand and Expanding Prescriber Base New Promotional Material Highlighting Long-Term OLE Data Prescriber and Patient Engagement ▪ Reinforces key message of durable corrective benefit with regular ▪ National broadcast during EB Awareness application of VYJUVEK gel
Slide 7: Poised for Significant Global Expansion in 2025
Poised for Significant Global Expansion in 2025 Europe Japan Over 1,000 Diagnosed DEB Over 500 Patients in France and Germany Alone Estimated DEB Patients in Japan EU CHMP opinion anticipated in 1Q 2025 | PMDA approval anticipated in 2H 2025 CHMP, Committee for Medicinal Products for Human Use; DEB,
Slide 8: Expedited Path to Top-Line Data for KB803 in Ocular Complications of DEB
Expedited Path to Top-Line Data for KB803 in Ocular Complications of DEB Ongoing: Natural History Study in DEB Patients ▪ Prospectively collecting data on frequency of corneal abrasions in 1H 2025 DEB patients First Patient Dosed 2H 2025 ▪ May also serve as run-in for patients Registrational Phase 3
Slide 9: Recent KB408 Readout Underscores Potential of HSV-1 in the Lung
Recent KB408 Readout Underscores Potential of HSV-1 in the Lung Over a third of airway cells in both patients were positive for AAT after a single KB408 dose Well tolerated in all seven Patient 06* 3% AAT Positive 35% Cells At Baseline AAT Positive Cells KB408 dosed patients to date After KB408** ✓
Slide 10: KB407 on Track for Molecular Data in Cystic Fibrosis Patients Later This Year
KB407 on Track for Molecular Data in Cystic Fibrosis Patients Later This Year Both single and repeat KB407 well tolerated in Cohorts 1 and 2 of CORAL-1 Phase 1 All Key Preclinical Criteria for KB407 Have Been Met 1. Airway Epithelial Cell Tropism ✓ No serious adverse events or dose-limiting toxiciti
Slide 11: Building on Our Clinical Momentum in 2025
Building on Our Clinical Momentum in 2025 Molecular data with KB407 and registrational KB803 study start over the next six months ❑ First patient dosed in Phase 3 study ❑ Top-line readout from KB407 Phase 1 evaluating KB803 (ophthalmic B-VEC) for cystic fibrosis including molecular for ocular DEB co
Slide 12: Fourth Quarter and Full Year 2024 Financial Highlights
Fourth Quarter and Full Year 2024 Financial Highlights Cash and investments: $749.6 million as of December 31, 2024 Three Months Ended Twelve Months Ended ($ in millions; except per share data) December 31 December 31 2024 2023 2024 2023 Product revenue, net $91.1 $42.1 $290.5 $50.7 Cost of goods so
Slide 13: Expecting a Catalyst Rich 2025
Expecting a Catalyst Rich 2025 ❑ EU CHMP opinion expected in 1Q 2025 and first European launch around mid 2025 ❑ Top-line readout from Phase 1 Cohort 3 evaluating KB407 in CF patients around mid 2025 ❑ Molecular data from Phase 1 Cohorts 2 and 3 evaluating KB408 in AATD patients in 2H 2025 ❑ First P
Slide 14: Developing Genetic Medicines to Treat Diseases with High Unmet Medical Needs
Developing Genetic Medicines to Treat Diseases with High Unmet Medical Needs © Copyright 2025 Krystal Biotech, Inc. All rights reserved.